Please select the option that best describes you:
Topics:
Breast Cancer • Radiation Oncology
Do you omit PMRT for patients that would have been eligible for NSABP B-51, but are found to have significant pure LVSI only, without stromal carcinoma, after neoadjuvant chemotherapy?
Would the ER/Her2 receptor subtype affect your answer?